1. Effects of AG-221 treatment on survival and cell differentiation in an IDH2R140Q primary human AML xenograft model.
Effects of AG-221 treatment on survival and cell differentiation in an IDH2R140Q primary human AML xenograft model. A, Study design outlining random allocation of mice into dosing groups. B, Kaplan–Meier survival curves in mice treated with vehicle, AG-221, or low dose Ara-C. Dosing was initiated when tumor burden was approximately 10% in PB/60% in BM (day 48). At day 84, surviving mice were terminated except for four animals in the AG mg/kg group, which remained on the same dose until study termination at day 130. P values for comparisons between treatment groups and vehicle were determined using the log-rank (Mantel–Cox) test. C, Percentage of blasts in BM aspirates on last day of treatment (day 84); 200 cells counted per slide from representative mice in each treatment group. Horizontal bars represent the mean; P values for comparisons between treatment groups and vehicle were determined using the t test. D, BM morphology in vehicle, AG mg/kg, and Ara-C 2 mg/kg groups. Wright-Giemsa stain, original magnification, ×1,000 oil. Representative results are shown.
Katharine Yen et al. Cancer Discov 2017;7:
©2017 by American Association for Cancer Research